Introduction to Lusutrombopag
Lusutrombopag, developed by Shionogi & Co., Ltd., is a small molecule drug that targets the thrombopoietin (TPO) receptor to treat thrombocytopenia, a condition characterized by a low platelet count. This drug has gained significant attention for its efficacy in treating patients with chronic liver disease (CLD) and other conditions associated with thrombocytopenia.
Market Size and Growth
The oral thrombopoietin receptor agonists market, which includes lusutrombopag, is experiencing robust growth. As of 2023, the global market size was estimated at $4.73 billion and is projected to reach $9.95 billion by 2034, growing at a compound annual growth rate (CAGR) of 7% from 2024 to 2034[1].
Segment Performance
By Type
The lusutrombopag segment is expected to witness notable growth within the oral thrombopoietin receptor agonists market. While eltrombopag currently holds a significant share due to its use in treating chronic immune thrombocytopenia (ITP), lusutrombopag is gaining traction for its effectiveness in treating thrombocytopenia associated with CLD. This drug is particularly valuable for patients undergoing invasive procedures, as it safely increases platelet counts and reduces the need for platelet transfusions[1].
By Application
The hospital and clinic segment dominates the market for oral thrombopoietin receptor agonists, including lusutrombopag. This is because these medications are primarily used to treat conditions such as ITP and CLD, which require professional supervision and care in hospital settings[1].
Regulatory Approvals and Clinical Trials
Lusutrombopag received its first approval in Japan in September 2015 and has since been approved in other countries globally. The drug has completed the highest phase of clinical trials and has been granted fast track status, indicating its potential to address an unmet medical need. This fast track designation underscores the drug's efficacy and safety profile[4].
Financial Performance of Shionogi & Co., Ltd.
Revenue and Sales
Shionogi & Co., Ltd. has seen significant revenue growth driven by the success of its new products, including lusutrombopag. In the financial year 2017, the company reported strong sales growth of strategic products, including an increase in royalty income from the HIV franchise and payments from Roche related to other projects. The sales of new products, such as lusutrombopag, contributed substantially to the company's revenue, with a notable increase in sales during this period[5].
Research and Development (R&D) Investments
Shionogi has been investing heavily in R&D, particularly in the global development of its strategic products. The company's R&D expenses have increased, reflecting its commitment to advancing clinical trials and obtaining regulatory approvals. For instance, the rolling submission of the New Drug Application (NDA) for lusutrombopag in the US was a key milestone, indicating the company's focus on expanding the drug's market reach[5].
Operating Income and Profit
The financial performance of Shionogi & Co., Ltd. has been influenced by the success of lusutrombopag and other new products. The company's operating income and profit have seen fluctuations, but overall, the growth in sales of strategic products has contributed positively to the company's financial trajectory. Despite some decreases in certain segments, the overall trend indicates a strong financial position driven by innovative products like lusutrombopag[3].
Regional Market Dynamics
The Asia Pacific region, particularly Japan, has been a significant market for lusutrombopag. The region's large population and growing investment in healthcare have boosted the demand for oral thrombopoietin receptor agonists. Shionogi & Co., Ltd.'s strong presence in Japan and its collaborations with other stakeholders have further enhanced the market growth in this region[1].
Competitive Landscape
The market for oral thrombopoietin receptor agonists is competitive, with several players involved in research and development. However, lusutrombopag's unique mechanism of action and its approval in multiple countries have positioned it as a valuable treatment option. Shionogi & Co., Ltd.'s strategic investments in R&D and its focus on global expansion have helped the company maintain a competitive edge in this market[4].
Future Outlook
Given the growing demand for effective treatments for thrombocytopenia and the expanding approvals for lusutrombopag, the financial trajectory for this drug is promising. The projected growth in the oral thrombopoietin receptor agonists market, coupled with Shionogi's continued investment in R&D, suggests that lusutrombopag will remain a significant contributor to the company's revenue and profitability in the coming years.
Key Takeaways
- Market Growth: The oral thrombopoietin receptor agonists market, including lusutrombopag, is expected to grow at a CAGR of 7% from 2024 to 2034.
- Segment Performance: Lusutrombopag is expected to witness notable growth, particularly in treating thrombocytopenia associated with CLD.
- Regulatory Approvals: Lusutrombopag has received approvals in multiple countries and has been granted fast track status.
- Financial Performance: Shionogi & Co., Ltd.'s revenue and profit have been positively impacted by the success of lusutrombopag.
- Regional Dynamics: The Asia Pacific region, especially Japan, is a significant market for lusutrombopag.
- Competitive Landscape: Lusutrombopag's unique mechanism and global approvals have positioned it as a valuable treatment option.
FAQs
-
What is lusutrombopag used for?
Lusutrombopag is used to treat thrombocytopenia, a condition characterized by a low platelet count, particularly in patients with chronic liver disease (CLD).
-
Who developed lusutrombopag?
Lusutrombopag was developed by Shionogi & Co., Ltd., a pharmaceutical company based in Japan.
-
What is the current market size for oral thrombopoietin receptor agonists?
As of 2023, the global market size for oral thrombopoietin receptor agonists was estimated at $4.73 billion.
-
What is the projected growth rate for the oral thrombopoietin receptor agonists market?
The market is projected to grow at a CAGR of 7% from 2024 to 2034.
-
Where was lusutrombopag first approved?
Lusutrombopag received its first approval in Japan in September 2015.
Sources
- Towards Healthcare: Oral Thrombopoietin Receptor Agonists Market Size, Shares and Trends.
- Shionogi Inc.: FY 2016 Financial Results.
- Shionogi Inc.: FY 2019 Financial Results.
- Synapse by PatSnap: Exploring lusutrombopag's Revolutionary R&D Successes.
- Shionogi Inc.: 1st Half of Fiscal 2017 Financial Results.
